Relationship between daytime sleepiness and methamphetamine taking
Active Project Grant Awarded Last action
- Award ID
- R36DA066826
- Recipient
-
University Of Mississippi Medical Center UEI X59NJBFL8BJ3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $54,000
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 14% complete
- Place of performance
- Jackson, MS 39216, USA
Award details come from USAspending.gov.
Description
- Abstract
- Methamphetamine use and its associated health consequences are becoming increasingly prevalent both in the united states and globally. Despite this growing public health concern, there are currently no FDA-approved pharmacotherapies for methamphetamine use disorder. Disturbed sleep-wake cycles are one of the most prominent consequences of methamphetamine use. While active methamphetamine use is associated with disrupted nighttime sleep, discontinuation of methamphetamine use is associated with excessive daytime sleepiness, which has been shown to predict greater methamphetamine craving. Despite the significance of excessive daytime sleepiness associated with discontinuation of methamphetamine use, this phenomenon has not been studied or modeled in the preclinical literature. The present project will model excessive daytime sleep following methamphetamine use in nonhuman primates, study its relationship to the more well described nighttime sleep disturbances observed with methamphetamine use, and investigate how MODAFINIL may mediate this interaction. Our working hypothesis is that chronic methamphetamine use causes excessive daytime sleepiness, and that continued methamphetamine use is driven, in part, by alleviation of associated excessive daytime sleepiness. Based on this hypothesis, we predict that a wakefulness-promoting drug (MODAFINIL) will improve sleep during abstinence and will reduce methamphetamine taking during ongoing self-administration through amelioration of excessive daytime sleepiness. Specific aim 1 will investigate the relationship between methamphetamine-induced daytime and nighttime sleep alterations during discontinuation of methamphetamine self-administration. Rhesus monkeys will self-administer methamphetamine intravenously for 7 consecutive days, and daytime/nighttime sleep will be evaluated for 2 weeks after discontinuation of methamphetamine self-administration using actigraphy. These studies will then be repeated with MODAFINIL administration during the first 7 days after discontinuation of methamphetamine self- administration. Specific aim 2 will investigate the relationship between methamphetamine-induced excessive daytime sleepiness and methamphetamine intake during active self-administration. Rhesus monkeys will self- administer methamphetamine for 7 consecutive days, followed by 7 more days of active self-administration and morning treatment with vehicle or MODAFINIL, and daytime/nighttime sleep will be evaluated during ongoing self- administration and after a 2-week discontinuation period. The use of this new translational model will allow for determination of the relationship between chronic methamphetamine use and excessive daytime sleepiness, as well as integration with evaluations of nighttime sleep disruptions. Moreover, our new model will allow evaluation of a potential treatment of excessive daytime sleepiness that may, in turn, reduce methamphetamine self- administration.
Quick answers
Who received award R36DA066826?
R36DA066826 was awarded to University Of Mississippi Medical Center by National Institute on Drug Abuse (National Institutes of Health) on September 15, 2026.
How much is award R36DA066826 worth?
$54,000 has been obligated on R36DA066826.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award